At day 54, the expression of CD206 mRNA, a M2-associated marker [40], was significantly downregulated by 56.6% (P = 0.05) and 62.9% (P = 0.04) in MDA-MB-231 tumor xenograft RNA samples from the F1- and F1Fc-treated group, respectively, compared with control (rituximab) (Fig. 5e). This evidence concerns the gene MRC1 and neoplasm.